Dr. Reddy's Laboratories (DRREDDY) — Financial Results

📢 Key Event
Dr. Reddy's Q1FY27 consolidated revenues rose 6% YoY to ₹8,071 crores

🔄 What Changed
PBT up 71% YoY to ₹553 crores; PAT up 69% YoY to ₹443 crores; EBITDA margin 12.5% (down from prior); semaglutide API impact of ₹240 crores noted

🔮 What's Next
No explicit future financial guidance or deadlines provided in the document

💡 Investor Takeaway
The company delivered strong profit growth despite semaglutide API headwinds, with cash surplus supporting continued strategic investments.

Dr. Reddy's Laboratories reported consolidated revenues of ₹8,071 crores for Q1FY27, reflecting 6% year-on-year growth and 7% quarter-on-quarter growth, driven by double-digit base business expansion across geographies. EBITDA reached ₹1,009 crores with a 12.5% margin, while profit before tax surged 71% YoY to [amount context mismatch] crores and profit after tax rose 69% YoY to ₹443 crores, aided by new product launches including generic semaglutide in Canada and bosutinib in the US. Excluding a ₹240 crore semaglutide API impact, revenues would have been ₹8,087 crores with an EBITDA margin of 15.4%. The company highlighted strong cash surplus of ₹3,058 crores and ongoing strategic initiatives in peptides, biosimilars, and consumer health, though it faced margin pressure from Middle East conflict-related cost increases and regulatory observations at its Bachupally facility.

📄 View Original Announcement (PDF)

📊 Stock Analysis — DRREDDY ✨ Ask AI About This

About Dr. Reddy's Laboratories Limited (DRREDDY)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,11,568.6 Cr P/E: 20.0 ROE: 16.6% ROCE: 19.7%

View full DRREDDY stock details →

📡 Get AI alerts when DRREDDY files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DRREDDY — Free

💡 Ask AI about this filing

"How does semaglutide API impact affect future margin guidance?" "What is the revenue contribution split between semaglutide and non-semaglutide segments?" "When will the Bachupally facility PLI observations be resolved?"

Ask AI Free →

📊 More DRREDDY filings

See all DRREDDY filings →

🔥 Also filed on 22 July 2026

SPLIL SPL Industries Limited Annual Report SIS SIS LIMITED Financial Results JAGSNPHARM Jagsonpal Pharmaceuticals Limited Financial Results PIRAMALFIN Piramal Finance Limited Financial Results HBSL HB Stockholdings Limited Annual Report VIJAYA Vijaya Diagnostic Centre Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DRREDDY files new disclosures

Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.